Lately, one of America's leading pharmaceutical companies can't catch a break from Wall Street. Shares of Vertex ...

The Massachusetts-based biotech plans to use the funds to push its candidates into mid-stage clinical trials in a space ...

Shares of Vertex Pharmaceuticals (NASDAQ ... caused by at least one of 303 possible mutations in their CFTR genes. Alyftrek's precursor, Trikafta, earned approval to treat cystic fibrosis patients ...

Learn more about whether Natera, Inc. or Vertex Pharmaceuticals Incorporated is a better investment based on AAII's A+ ...

Unfortunately, the stock market barely noticed Vertex's achievement ... by at least one of 303 possible mutations in their CFTR genes. Alyftrek's precursor, Trikafta, earned approval to treat ...

Vertex received FDA approval for the expanded use of TRIKAFTA in patients with 94 additional non-F508del CFTR mutations. With this approval, approximately 300 people in the U.S. are newly eligible ...

FDA approval of ALYFTREK and TRIKAFTA expands CF treatment options to over 300 mutations, benefiting 300 ... Earnings Report RBC Capital Markets says Vertex management is optimistic about the ...

TRIKAFTA: Also on December 20, 2024, Vertex received FDA approval for the expanded use of TRIKAFTA in patients with 94 additional non-F508del CFTR mutations. With this approval, approximately 300 ...